Company intelligence / Profile preview

Guangzhou Yaoguang Technology

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Guangzhou Yaoguang Technology is a clinical-stage biotechnology company focused on the development of innovative ophthalmic treatments. The company utilizes its proprietary sustained-release drug delivery platform to create long-acting therapies for chronic eye diseases. Its lead program, YG-001, is a bimatoprost-loaded sustained-release implant currently in clinical development for the treatment of glaucoma and ocular hypertension. Yaoguang Technology aims to address the challenges of patient compliance and treatment efficacy in ophthalmology through advanced formulation science. The company is backed by prominent life science investors and is headquartered in Guangzhou, China.

Therapeutic areas: Ophthalmology
Modalities: Small moleculeSustained-release implant
Industry: Biotech

Beyond the preview

Go deeper on Guangzhou Yaoguang Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Yaoguang Technology.

Explore the full profile